The Role of Hospital Pharmacists in Supporting the Appropriate and Safe Use of CGT/ATMPs: a Scoping Review of Current Insights

Overview

Journal BMC Health Serv Res

Publisher Biomed Central

Date 2025 Jan 9

PMID 39789612

Authors

Junnan Shi

Xianwen Chen

Hao Hu

Carolina Oi Lam Ung

Affiliations

Soon will be listed here.

Abstract

Background: The role of hospital pharmacists in managing cell and gene therapy (CGT) and advanced therapy medicinal products (ATMPs) is gradually being recognized but the evidence about impact of their role has not been systematically reported.

Objective: This study was aimed to summarize the professional services provided by hospital pharmacists on managing CGT/ATMPs and the evidence about the effects on patient care, as well as to identify the perceptions about pharmacists assuming a role that supports the appropriate and safe use of CGT/ATMPs.

Methods: Literature from 4 electronic databases (PubMed, ScienceDirect, Web of Science, Scopus) were searched following PRISMA checklist to yield publications on the interventions provided by hospital pharmacists in the management of CGT/ATMPs dated since 1 January 2013 till 30 April 2023.

Results: Thirty-four publications were included in this review. Eight studies involving hospital pharmacists participating in interventions for 1,012 hematopoietic stem cell transplant (HSCT) patients from 8 hospitals in 5 countries were identified. Common pharmacist-led interventions centered on medicine administration, prescribing, and monitoring of medicines use, resulting in significant improvement in patient adherence, satisfaction and knowledge. Of 26 studies, the perspectives assuming their roles in CGT/ATMPs management were categorized when patients receiving ATMPs (n = 2), HSCT and cellular-based therapy (n = 12), gene therapy (n = 6), and the chimeric antigen receptor (CAR) T-cell therapy (n = 6), mainly covering procurement, influences on prescribing, preparation and delivery, administration, monitoring of medicines use, human resources, training and development. The anticipated impact was primarily intended to promote pharmacy practice, multidisciplinary collaboration and improve patient clinical outcomes.

Conclusion: Leveraging the role of hospital pharmacists in multidisciplinary healthcare teams to develop a coordinated approach that supports pharmacy practice will better meet the management of CGT/ATMPs. For hospital pharmacists to step up their role in the multidisciplinary healthcare team, advancing their skillset in terms of clinical practice standards and medication management is essential.

References

Langebrake C, Admiraal R, van Maarseveen E, Bonnin A, Bauters T . Consensus recommendations for the role and competencies of the EBMT clinical pharmacist and clinical pharmacologist involved in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019; 55(1):62-69. DOI: 10.1038/s41409-019-0538-9. View

Frey B, Humpe A . ATMPs: New Challenge for Transfusion Services. Transfus Med Hemother. 2022; 49(3):127-128. PMC: 9209980. DOI: 10.1159/000525025. View

Mebarki M, Madelaine I, Larghero J, De Jorna R . Advanced therapy medicinal products: Regulatory framework, hospital and pharmaceutical circuits in Europe and France. Therapie. 2021; 77(2):185-190. DOI: 10.1016/j.therap.2021.11.005. View

Canfield S . Decoding gene therapy: Current impact and future considerations for health-system and specialty pharmacy practice. Am J Health Syst Pharm. 2021; 78(11):953-961. DOI: 10.1093/ajhp/zxab064. View

Park S, Daugherty K, Kolluru S, Lebovitz L, Gunaseelan S, Janetski B . Rethinking the Pharmacy Workforce Crisis by Exploring Unconventional and Emerging Career Pathways and Training. Am J Pharm Educ. 2021; 86(6):8773. PMC: 10159434. DOI: 10.5688/ajpe8773. View

Mahmoudjafari Z, Hawks K, Hsieh A, Plesca D, Gatwood K, Culos K . American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States. Biol Blood Marrow Transplant. 2018; 25(1):26-33. DOI: 10.1016/j.bbmt.2018.09.024. View

Shah K, Kogut S, Slitt A . Challenges in Evaluating Safety and Efficacy in Drug Development for Rare Diseases: A Review for Pharmacists. J Pharm Pract. 2020; 34(3):472-479. DOI: 10.1177/0897190020930972. View

Marzal-Alfaro M, Escudero-Vilaplana V, Revuelta-Herrero J, Collado-Borrell R, Herranz-Alonso A, Sanjurjo-Saez M . Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective. Front Oncol. 2021; 11:636068. PMC: 7992774. DOI: 10.3389/fonc.2021.636068. View

Ramezankhani R, Torabi S, Minaei N, Madani H, Rezaeiani S, Hassani S . Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies. Front Cell Dev Biol. 2021; 8:547653. PMC: 7773756. DOI: 10.3389/fcell.2020.547653. View

10.

Duncan N, Moreno-Martinez M, Pires V, Domingos V, Bonnin A, Nezvalova-Henriksen K . Role and competencies of the EBMT clinical pharmacists and clinical pharmacologists: a pan-European survey. Bone Marrow Transplant. 2023; 58(7):829-831. DOI: 10.1038/s41409-023-01983-9. View

11.

Petrich J, Marchese D, Jenkins C, Storey M, Blind J . Gene Replacement Therapy: A Primer for the Health-system Pharmacist. J Pharm Pract. 2019; 33(6):846-855. PMC: 7675776. DOI: 10.1177/0897190019854962. View

12.

Andrick B, Tusing L, Jones L, Hu Y, Sneidman R, Gregor C . The Impact of a Hematopoietic Cellular Therapy Pharmacist on Clinical and Humanistic Outcomes: A RE-AIM Framework Analysis. Transplant Cell Ther. 2022; 28(6):334.e1-334.e9. DOI: 10.1016/j.jtct.2022.02.015. View

13.

Blind J, Nowicki D, McConnell K, Motsney A, Kong A . A call to action: Health-system pharmacists must stand up to meet the growing demand for cellular-based therapies. Am J Health Syst Pharm. 2023; 80(14):944-947. DOI: 10.1093/ajhp/zxad071. View

14.

Segal E, Bates J, Fleszar S, Holle L, Kennerly-Shah J, Rockey M . Demonstrating the value of the oncology pharmacist within the healthcare team. J Oncol Pharm Pract. 2019; 25(8):1945-1967. DOI: 10.1177/1078155219859424. View

15.

Iglesias-Lopez C, Agusti A, Obach M, Vallano A . Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States. Front Pharmacol. 2019; 10:921. PMC: 6728416. DOI: 10.3389/fphar.2019.00921. View

16.

Kozma C, Reeder C, Schulz R . Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther. 1993; 15(6):1121-32; discussion 1120. View

17.

Hernandez J . Biosafety Considerations for Viral Vector Gene Therapy: An Explanation and Guide for the Average Everyday-Hero Pharmacist. J Pharm Pract. 2022; 36(6):1532-1539. DOI: 10.1177/08971900221104250. View

18.

Iglesias-Lopez C, Obach M, Vallano A, Agusti A . Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Cytotherapy. 2021; 23(3):261-274. DOI: 10.1016/j.jcyt.2020.11.008. View

19.

Sah S, R S, Ramesh M, Chand S . Impact of pharmacist care in the management of autoimmune disorders: A systematic review of randomized control trials and non-randomized studies. Res Social Adm Pharm. 2021; 17(9):1532-1545. DOI: 10.1016/j.sapharm.2020.12.005. View

20.

Blind J, McLeod E, Campbell K . Viral-mediated gene therapy and genetically modified therapeutics: A primer on biosafety handling for the health-system pharmacist. Am J Health Syst Pharm. 2019; 76(11):795-802. DOI: 10.1093/ajhp/zxz056. View